Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyoto University
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons; Ribavirin

Criteria

Inclusion Criteria:

• Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection.

• Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy

Exclusion Criteria:

• No recurrence of hepatocellular carcinoma 3 months after the primary treatment

• Renal dysfunction